Skip to main content
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC — Investor Relations & Filings

Ticker · CGTX ISIN · US19243B1026 US Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2022-08-09 Earnings Release
Country US United States of America
Listing US CGTX

About COGNITION THERAPEUTICS INC

https://cogrx.com/

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company that discovers and develops oral, small-molecule therapeutics for neurodegenerative disorders. The company's primary focus is on conditions such as Alzheimer's disease and Dementia with Lewy Bodies (DLB). Its therapeutic approach is centered on developing medications designed to target and modulate key cellular damage response mechanisms. By aiming to rescue trafficking deficits and restore normal cellular housekeeping functions, the company seeks to protect neurons, improve synaptic health, and ultimately address the cognitive decline associated with these diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2022, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2022. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, and is not incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3899 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE, this document is an announcement of a report (the earnings release) rather than the report itself. Hence, the appropriate classification is Earnings Release (ER).
2022-08-09 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 21, 2022, reporting the departure of the Chief Financial Officer and the appointment of an Interim Chief Financial Officer. The content focuses on changes in senior management personnel, including details about severance and appointment terms. There are no financial statements or detailed financial performance data present. The document is a regulatory announcement about management changes, fitting the category of Board/Management Information (MANG).
2022-07-27 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-06-30 English
AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-06-23 English
AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-06-23 English
AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-06-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.